###begin article-title 0
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 340 343 340 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET</italic>
###xml 353 357 353 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 465 469 465 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
Germline mutations in RET are responsible for multiple endocrine neoplasia type 2 (MEN2), an autosomal dominantly inherited cancer syndrome that is characterized by medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid hyperplasia/adenoma. Recent studies suggest a "second hit" mechanism resulting in amplification of mutant RET. Somatic VHL gene alterations are implicated in the pathogenesis of MEN2 pheochromocytomas. We hypothesized that somatic VHL gene alterations are also important in the pathogenesis of MEN2-associated MTC.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 226 230 226 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
We analyzed 6 MTCs and 1 C-cell hyperplasia (CCH) specimen from 7 patients with MEN2A and RET germline mutations in codons 609, 618, 620, or 634, using microdissection, microsatellite analysis, phosphorimage densitometry, and VHL mutation analysis.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 334 338 334 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 361 365 361 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 474 477 474 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET</italic>
###xml 644 648 644 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 660 664 660 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 690 694 690 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 758 762 758 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 784 788 784 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
First, we searched for allelic imbalance between mutant and wild-type RET by using the polymorphic markers D10S677, D10S1239, and RET on thyroid tissue from these patients. Evidence for RET amplification by this technique could be demonstrated in 3 of 6 MTCs. We then performed LOH analysis using D3S1038 and D3S1110 which map to the VHL gene locus at 3p25/26. VHL gene deletion was present in 3 MTCs. These 3 MTCs also had an allelic imbalance between mutant and wild-type RET. Mutation analysis of the VHL gene showed a somatic frameshift mutation in 1 MTC that also demonstrated LOH at 3p25/26. In the 2 other MTCs with allelic imbalance of RET and somatic VHL gene deletion, no somatic VHL mutation could be detected. The CCH specimen did neither reveal RET imbalance nor somatic VHL gene alterations.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
These data suggest that a RET germline mutation is necessary for development of CCH, that allelic imbalance between mutant and wild-type RET may set off tumorigenesis, and that somatic VHL gene alterations may not play a major role in tumorigenesis of MEN2A-associated MTC.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 331 335 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 397 401 397 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 462 463 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 464 465 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 515 519 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 719 720 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 721 722 721 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 723 724 723 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 820 821 820 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 986 990 986 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 1060 1064 1060 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 1143 1145 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1146 1148 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1159 1163 1159 1163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 1299 1301 1299 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1344 1348 1344 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 295 303 <span type="species:ncbi:9606">Patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
###xml 972 980 <span type="species:ncbi:9606">patients</span>
Medullary thyroid carcinoma (MTC) develops from the parafollicular C cells in the thyroid gland and occurs sporadically as well as in the hereditary syndrome multiple endocrine neoplasia type 2 (MEN2). The gene responsible for MEN2 is the RET protooncogene, located at chromosome 10q11.2 [1,2]. Patients with germline mutations in RET invariably develop MTC, although there are some patients with RET germline mutations who have lived beyond age 70 without MTC [3,4]. Therefore, patients with germline mutations in RET usually are divided into different risk groups (low, intermediate, and high risk for developing MTC). So-called low-risk or level I mutations include those at codons 609, 768, 790, 791, 804, and 891 [1,5-8]. Hyperplasia of the parafollicular C cells has been regarded as the precursor lesion for MTC [9,10]. Accumulating evidence suggests that a 'second hit' or additional genetic events may be required to set off tumorigenesis in susceptible cells of patients with RET germline mutations. An allelic imbalance between mutant and wild-type RET may represent the decisive step of tumorigenesis for MTC and pheochromocytoma [11-15]. Somatic VHL gene alterations are implicated in the pathogenesis of MEN2-associated pheochromocytomas, possibly through accumulation of RET protein [16]. Therefore, we hypothesized that somatic VHL gene alterations may also play a role in the pathogenesis of MEN2-associated MTC.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and tissues
###end title 13
###begin p 14
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 97 104 <span type="species:ncbi:9606">patient</span>
###xml 125 132 <span type="species:ncbi:9606">patient</span>
###xml 156 163 <span type="species:ncbi:9606">patient</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 370 377 <span type="species:ncbi:9606">patient</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
Seven patients with MEN2A and RET germline mutations in codons 609 (4 patients, Leipzig), 618 (1 patient, St. Louis), 620 (1 patient, St. Louis), or 634 (1 patient, NIH) underwent total thyroidectomy at the Washington University in St. Louis, MO, the National Institutes of Health in Bethesda, and the University of Leipzig, Germany. In 6 patients, MTC was diagnosed; 1 patient had C cell hyperplasia (Tables 1 and 2). None of the patients had clinical evidence for VHL syndrome and was analyzed for germline mutations in the VHL gene.
###end p 14
###begin p 15
###xml 38 39 38 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Two specimens (cases 1 and 2 in Table 1) were previously analyzed for imbalance of the mutant and wild-type RET allele (see Ref. [12]).
###end p 15
###begin p 16
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Frozen or paraffin-embedded tissue was microdissected and analyzed for loss of heterozygosity (LOH) by polymorphic markers mapping to the VHL gene locus, as previously described [16].
###end p 16
###begin p 17
###xml 186 189 186 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET</italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Tissue was obtained from these 7 patients under an Internal Review Board (IRB)-approved protocol at the National Institutes of Health. All of them had MEN 2A with a germline mutation in RET. Blood was drawn for DNA extraction. Thyroid specimens including MTC were removed at the time of surgery and frozen at -80degreesC. DNA was extracted from lymphoblasts and tumor tissue by standard methods.
###end p 17
###begin p 18
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
Six-micron sections were obtained from frozen tumor and briefly stained with hematoxylin and eosin (H & E). If no frozen tumor was available, paraffin-embedded tissue was prepared for microdissection. Under direct light microscopic visualization using a 30-gauge needle, a modified microdissection procedure was performed, as previously described [17]. In all cases, we obtained also samples of nontumor control tissue from the same slides.
###end p 18
###begin title 19
Allelic imbalance of the RET gene locus and loss of heterozygosity of the VHL gene locus
###end title 19
###begin p 20
###xml 35 38 35 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET</italic>
###xml 255 257 255 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 561 565 541 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 592 596 566 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
We performed imbalance analyses of RET, using polymorphic markers/primers D10S677, D10S1239, and RET for the RET locus, and loss of heterozygosity studies using markers D3S1038 and D3S1110 which map to the VHL gene locus 3p25/26 in the presence of [alpha-32P] dCTP (0.1 muCi/mul) (Dupont). PCR conditions using AmpliTaq Gold DNA polymerase (Perkin Elmer Roche) in a Hybaid Omnigene thermal cycler were as follows: initial denaturation at 95degreesC for 10 min, then 35 cycles, each with 1 min of denaturation at 95degreesC, 1 min of annealing at 55degreesC for RET markers, at 60degreesC for VHL markers, and 1 min of extension at 72degreesC; PCR was completed with a final extension at 72degreesC for 10 min. The amplicons were resolved on a 6% polyacrylamide gel. Gels were dried and exposed to Kodak XAR film. All PCR reactions were performed in triplicate.
###end p 20
###begin title 21
VHL gene mutation analysis
###end title 21
###begin p 22
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Exons 1-3 of the VHL gene were amplified from genomic DNA using polymerase chain reaction conditions described elsewhere [18]. Mutation scanning by conformation sensitive gel electrophoresis (CSGE) was performed on the PCR products as described by Ganguly et al. [19]. DNA sequence analysis was performed using a cycle sequencing kit with dye-labeled terminators (PE Advanced Biosystems, Inc., Foster City, CA). Sequences were analyzed on an ABI 377 automated DNA sequencer.
###end p 22
###begin title 23
Results
###end title 23
###begin p 24
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
We studied 6 medullary thyroid carcinomas and 1 C-cell hyperplasia specimen from 7 patients with MEN 2A and known RET germline mutations for allelic imbalance at the RET locus and for somatic genetic alterations at the VHL gene locus at 3p25/26 including LOH and mutations (Table 1). Allelic imbalance between the mutant and wild-type RET allele could be demonstrated in 3 MTCs (Fig. 1). The same 3 tumors also had LOH of the VHL gene locus (Fig. 2).
###end p 24
###begin p 25
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 498 502 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 556 560 556 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 798 802 798 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 805 809 805 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 834 837 834 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL</italic>
To further investigate whether inactivation of the VHL tumor suppressor gene plays a role in tumorigenesis of MEN 2A-related MTC, we performed mutation analysis of the VHL gene and found mutations in at least 1 of the 7 C- cell specimens (Figs. 3 and 4, Table 1). Mutation analysis of the VHL gene showed a frameshift mutation in 1 MTC. This tumor had simultaneously LOH at the RET and VHL gene locus (case 1 in Table 1). Another tumor (case 2) had LOH at the RET and VHL gene locus but no somatic VHL mutation. In cases 3 and 4, the mutation analysis for VHL could not be completely performed (exon 1 was analyzed and negative for mutations; exons 2 and 3 could not be analyzed) because of technical problems and no further DNA left. Cases 5 and 6 (MTC) as well as case 7 (CCH) had neither LOH at RET or VHL nor somatic mutations of VHL.
###end p 25
###begin title 26
Discussion
###end title 26
###begin p 27
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
In this study, we show that somatic VHL mutation and deletion are involved in tumor progression rather than tumor initiation of MEN 2A-related MTC. In both sporadic and familial forms of MTC, allelic losses at 1p, 3, 4, 9q, 10q, 13q, and 22q have been reported [20-24]. Specific tumor suppressor genes or oncogenes at these chromosomal loci, however, have rarely been analyzed.
###end p 27
###begin p 28
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 340 344 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
In sporadic pheochromocytomas, somatic mutations of VHL or RET are found in less than 10% of tumors, suggesting a possible role in tumorigenesis, whereas the prevalence and role of such mutations in hereditary pheochromocytomas such as those occurring in MEN 2 is not known. In a recent study, we detected inactivating somatic mutations of VHL and LOH at 3p25/26 in several MEN 2A-related pheochromocytomas [16]. In all of these MEN 2A-associated pheochromocytomas as well as in the present study of thyroid C cell specimens, regular wild-type VHL alleles were detected in normal control tissue confirming the presence of two wild-type alleles and excluding the presence of VHL disease.
###end p 28
###begin p 29
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 643 647 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
VHL disease consists of a variety of tumors including pheochromocytoma [25,26]. However, MTC is not part of VHL syndrome, although MTC was found (likely coincidentally) in 2 patients with VHL germline mutation [27]. Mutations in the VHL gene lead to constitutive expression of many hypoxia-inducible genes, in part related to increasing levels of hypoxia-inducible transcription factor (HIF) 1-alpha which in normal cells is rapidly ubiquitinated and degraded [28]. VHL protein, a ubiquitinase adapter, plays a role in cell-cycle control, differentiation, extracellular matrix formation and turnover, and angiogenesis. Therefore, mutations in VHL may lead to an absent or reduced VHL protein function with reduced degradation of proteins including RET protein. In addition to other events, RET protein accumulation secondary to absent or reduced VHL protein, may then cause further transformation of selected parafollicular C-cells.
###end p 29
###begin p 30
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 246 250 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 481 482 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 519 523 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 590 594 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 722 725 722 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET</italic>
###xml 773 777 773 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 901 905 901 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 938 942 938 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 1088 1092 1088 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 1171 1180 1171 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53, RB1</italic>
###xml 1186 1190 1186 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT1 </italic>
###xml 1191 1193 1191 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1225 1229 1225 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 1336 1340 1336 1340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 1359 1361 1359 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1362 1364 1362 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1382 1384 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1527 1529 1527 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1693 1696 1693 1696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET</italic>
###xml 1706 1710 1706 1710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 1780 1784 1780 1784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 1857 1859 1857 1859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1860 1862 1860 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1972 1974 1972 1974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1991 1993 1991 1993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2148 2152 2148 2152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 2398 2400 2398 2400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 2453 2457 2453 2457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 2469 2473 2469 2473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 2590 2594 2590 2594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
###xml 566 574 <span type="species:ncbi:9606">patients</span>
###xml 615 622 <span type="species:ncbi:9606">patient</span>
###xml 1074 1082 <span type="species:ncbi:9606">patients</span>
###xml 1320 1328 <span type="species:ncbi:9606">patients</span>
###xml 1584 1592 <span type="species:ncbi:9606">patients</span>
###xml 1764 1772 <span type="species:ncbi:9606">patients</span>
Although a 'second hit' which usually consists of deletion in the wild-type VHL allele, is necessary for initiation of tumor growth in patients with VHL germline mutations, it may not be sufficient [26,29,30]. Similarly, in patients with MEN2, a RET germline mutation is necessary for formation of MTC and pheochromocytoma, but may not be sufficient, as there are patients who have never developed MTC or pheochromocytoma during their life or developed MTC late in their lifetime [3,4,31-33]. Here, we detected somatic VHL gene alterations in 3 of 6 MTCs from MEN2A patients and no somatic VHL gene alteration in 1 patient with MEN2A and CCH. In addition, all 3 MTCs with LOH at the VHL gene also had allelic imbalance of RET. However, in only one of these MTCs, a somatic VHL mutation was found in addition to LOH at the VHL gene. In our single case of CCH, no imbalance between mutant and wild-type RET has been detected and no somatic VHL gene alteration. Therefore, additional somatic mutational events including the VHL gene may be required to set off tumorigenesis in patients with RET germline mutations. CCH foci have heterogeneous DNA deletions including LOH of TP53, RB1, and WT1 [34]. Polymorphisms G691S/S904S of RET have recently been found to affect the development of MTC and the age at onset of MEN2A in patients with a RET germline mutation [35-37]. Elisei et al. [36] found a statistically significant higher allelic frequency of G691S polymorphism in MTCs than that found in normal controls. Cebrian et al. [37] carried out an association study in 135 sporadic MTC patients and 533 controls and discovered a strong association between the disease and specific haplotypes of RET. Somatic RET mutations such as M918T in MTC or pheochromocytoma of patients with a RET germline mutation appear to represent a phenomenon of tumor progression [38-43]. Chromosomal imbalances in MTC include deletions of chromosomes 1p, 3q26.3-q27, 4, 9q13-q22, 13 q, and 22q [24]. Marsh et al. [24] found loss of whole or partial chromosome 3 including the region of the VHL locus as the predominant imbalance (40% of cases). Biallelic inactivation of VHL should lead to loss of VHL protein. Using immunohistochemistry, VHL protein is detectable in thyroid follicles and differentiated tumors derived from follicular epithelium, but is weakly or not detectable in nonneoplastic and neoplastic C cells [44]. Since, in our study, neither allelic imbalance of RET nor somatic VHL gene alterations occurred in the CCH specimen (presumably the precursor lesion of MTC), we suggest that such somatic VHL gene alterations rather play a role in tumor progression than in tumor formation of MEN2-related MTC. This interpretation is based on a single case of CCH and would require confirmation in studies of larger size.
###end p 30
###begin title 31
Conclusion
###end title 31
###begin p 32
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 317 321 317 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
Tumor formation in these selected MEN 2A-related MTCs may have occurred by first, a RET germline mutation, leading to hyperplasia of C cells and second, an amplification event of mutant RET which, however, could not be consistently detected by the methods used by us (polymorphic marker analysis). Subsequent somatic VHL gene deletion and mutation in selected C cells may lead to further transformation and tumor progression. However, given the small sample size, it is possible that tumor formation and progression in a significant number of tumors may occur by other mechanisms.
###end p 32
###begin title 33
Abbreviations
###end title 33
###begin p 34
MTC - medullary thyroid carcinoma; CCH - c cell hyperplasia; MEN2 - multiple endocrine neoplasia type 2, LOH - loss of heterozygosity; VHL - von Hippel Lindau
###end p 34
###begin title 35
Competing interests
###end title 35
###begin p 36
The author(s) declare that they have no competing interests.
###end p 36
###begin title 37
Authors' contributions
###end title 37
###begin p 38
CAK designed this study, carried out bench experiments related to this study, interpreted the results, drafted the paper, and finalized the manuscript after input from the other authors.
###end p 38
###begin p 39
FBM helped carrying out bench experiments related to this paper. AOV provided microdissection of material used for this study, helped in interpreting the results and drafting the paper by providing critical intellectual input. AT provided material for this paper and helped drafting the paper. SKL provided material for this paper and helped drafting the paper.
###end p 39
###begin p 40
ZZ helped in interpreting the results of this study. KP helped providing material for this paper and drafting the paper. HPHN helped in carrying out bench experiments and drafting the paper. RP provided intellectual input in drafting of the paper. All authors read and approved the final version of the manuscript.
###end p 40
###begin title 41
Pre-publication history
###end title 41
###begin p 42
The pre-publication history for this paper can be accessed here:
###end p 42
###begin p 43

###end p 43
###begin title 44
Acknowledgements
###end title 44
###begin p 45
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
We thank Jeffrey Moley, MD, from the Washington University in St. Louis, for providing MTC samples (here: cases 1 and 2), and Catherine Stolle, PhD, from the University of Pennsylvania School of Medicine, for analyzing samples for VHL mutations. We also thank Celso Gomez-Sanchez, MD, from the University of Mississippi, for technical support.
###end p 45
###begin article-title 46
Consensus guidelines for diagnosis and therapy of MEN type I and type 2
###end article-title 46
###begin article-title 47
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis
###end article-title 47
###begin article-title 48
RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia 2A syndrome?
###end article-title 48
###begin article-title 49
RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed?
###end article-title 49
###begin article-title 50
Multiple endocrine neoplasia type 2. Evaluation of the genotype-phenotype relationship
###end article-title 50
###begin article-title 51
European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer
###end article-title 51
###begin article-title 52
Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation
###end article-title 52
###begin article-title 53
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma
###end article-title 53
###begin article-title 54
Natural history of the familial medullary thyroid carcinoma-pheochromocytoma syndrome and the identification of preneoplastic stages by screening studies: a five-year report
###end article-title 54
###begin article-title 55
C-cell hyperplasia preceding medullary thyroid carcinoma
###end article-title 55
###begin article-title 56
Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas
###end article-title 56
###begin article-title 57
Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma
###end article-title 57
###begin article-title 58
Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma
###end article-title 58
###begin article-title 59
The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors
###end article-title 59
###begin article-title 60
Molecular pathogenesis of MEN2-associated tumors
###end article-title 60
###begin article-title 61
Somatic VHL gene deletion and point mutation in MEN2A-associated pheochromocytomas
###end article-title 61
###begin article-title 62
Applications of tissue microdissection in cancer genetics
###end article-title 62
###begin article-title 63
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene
###end article-title 63
###begin article-title 64
Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes
###end article-title 64
###begin article-title 65
Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas
###end article-title 65
###begin article-title 66
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes
###end article-title 66
###begin article-title 67
Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2
###end article-title 67
###begin article-title 68
CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome
###end article-title 68
###begin article-title 69
Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma
###end article-title 69
###begin article-title 70
von Hippel-Lindau disease
###end article-title 70
###begin article-title 71
Developmental effects of von Hippel-Lindau gene deficiency
###end article-title 71
###begin article-title 72
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II
###end article-title 72
###begin article-title 73
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex
###end article-title 73
###begin article-title 74
Effects of VHL deficiency on endolymphatic duct and sac
###end article-title 74
###begin article-title 75
Second hit deletion size in von Hippel-Lindau disease
###end article-title 75
###begin article-title 76
Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer
###end article-title 76
###begin article-title 77
Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804
###end article-title 77
###begin article-title 78
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma
###end article-title 78
###begin article-title 79
Germline RET 634 mutation positive MEN 2A-related C-cell hyperplasias have genetic features consistent with intraepithelial neoplasia
###end article-title 79
###begin article-title 80
Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A
###end article-title 80
###begin article-title 81
RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population
###end article-title 81
###begin article-title 82
Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma
###end article-title 82
###begin article-title 83
Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma
###end article-title 83
###begin article-title 84
Somatic mutations of the RET proto-oncogene are not required for tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers
###end article-title 84
###begin article-title 85
Somatic mutations in the RET protooncogene in sporadic medullary thyroid carcinoma
###end article-title 85
###begin article-title 86
Novel somatic mutation in the RET proto-oncogene in familial medullary thyroid carcinoma with a germline codon 768 mutation
###end article-title 86
###begin article-title 87
Do somatic RET mutations represent a phenomenon of tumor progression ?
###end article-title 87
###begin article-title 88
Loss of heterozygosity at the RET protooncogene locus in a case of multiple endocrine neoplasia type 2A
###end article-title 88
###begin article-title 89
Expression of the von Hippel-Lindau tumor suppressor gene in nonneoplastic and neoplastic lesions of the thyroid
###end article-title 89
###begin title 90
Figures and Tables
###end title 90
###begin p 91
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
###xml 0 138 0 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Allelic imbalance of mutant and wild-type <italic>RET </italic>in one representative case (case 3, Table 1) of MEN2A-associated medullary thyroid carcinoma</bold>
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET </italic>
Allelic imbalance of mutant and wild-type RET in one representative case (case 3, Table 1) of MEN2A-associated medullary thyroid carcinoma. T3, tumor from case 3; N, normal tissue; D10S677, polymorphic marker. The arrows indicate the 2 RET alleles.
###end p 91
###begin p 92
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LOH analysis of the <italic>VHL </italic>gene locus of 3 cases of MEN 2A-related MTCs with marker D3S1038 or D3S1110</bold>
###xml 265 269 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
LOH analysis of the VHL gene locus of 3 cases of MEN 2A-related MTCs with marker D3S1038 or D3S1110. All cases show loss of one allele in microdissected tumor tissue (T), whereas heterozygosity is retained in normal non-neoplastic tissue (N). Arrows indicate the 2 VHL alleles.
###end p 92
###begin p 93
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Somatic mutation of the VHL gene in MEN2-associated MTC</bold>
###xml 96 103 96 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink">case 1 </bold>
###xml 511 516 511 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 681 686 681 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
Somatic mutation of the VHL gene in MEN2-associated MTC. Portion of the sequence of exon 1 from case 1 demonstrating a deletion of a single base (del C) at nucleotide 389 of the VHL gene in one allele at the position indicated by the arrow. This mutation would result in a shift in the translational frame of the encoded mRNA from codon 59 to a premature stop codon at position 66. Exons 1-3 of the VHL gene were amplified from genomic DNA using polymerase chain reaction conditions described elsewhere (Stolle et al.,1998). Mutation scanning by conformation sensitive gel electrophoresis (CSGE) was performed on the PCR products obtained using PCR conditions described by Ganguly et al., 1993. DNA sequence analysis was performed using a cycle sequencing kit with dye-labeled terminators (PE Advanced Biosystems, Inc., Foster City, CA). Sequences were analyzed on an ABI 377 automated DNA sequencer.
###end p 93
###begin p 94
Normal sequence of the VHL gene, portion of exon 1, compared to mutant sequence in figure 3.
###end p 94
###begin p 95
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 120 123 120 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RET</italic>
Somatic VHL gene deletion and mutation in MEN 2A-associated medullary thyroid carcinomas/CCH with germline mutations of RET
###end p 95
###begin p 96
N/A, not available
###end p 96
###begin p 97
Clinical features
###end p 97
###begin p 98
N/A, not available; HTN, hypertension
###end p 98

